|
Improving IHC reference standards
October 2016
SHARING OPTIONS:
CAMBRIDGE, U.K.—Horizon Discovery Group plc and Ventana Medical Systems Inc., a member of the Roche Group, joined forces in a co-development and commercialization agreement in early September.
The agreement will cover the development, manufacture and commercialization of cell line derivative materials for use as immunohistochemistry (IHC) reference
standards in cancer tissue diagnostics to support development and validation of IHC assays. Per the agreement, Ventana has an option to commission projects
from Horizon, with Horizon developing applicable cell lines and associated derivative reference standard materials. Horizon will be primarily responsible for
commercializing the reference standards and will serve as primary distribution channel. Ventana will have the option to co-distribute any developed reference
standards.
Paul Morrill, president of products at Horizon, stated that “We are excited to continue to strengthen our
relationship with Ventana, developing reference standards in areas of significant need and exploring the opportunity for follow-on OEM
agreements.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|